Form 4 for TNYA Tenaya Therapeutics, Inc.
Accepted 2026-02-17 00:00:00 ET · period of report 2026-02-17 · accession 0001193125-26-055442 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-02-17 | 2026-02-17 | TNYA | Ali Faraz | CEO, Dir | S - Sale | $0.64 | -14.9K | 448.4K | -3% | -$9,512 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-17 | S | D | 5,032 | $0.64 | 443,404 | D | — | — | (F2) Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. (F7) Includes 330,187 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. |
| 2 | Common | Common Stock | 2026-02-17 | S | D | 5,851 | $0.64 | 452,415 | D | — | — | (F2) Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. (F3) Includes 354,250 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. |
| 3 | Common | Common Stock | 2026-02-17 | S | D | 3,979 | $0.64 | 448,436 | D | — | — | (F2) Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. (F5) Includes 343,625 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. |